Telangana unveils ambitious next-gen Life Sciences Policy at Davos

A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics

EMA hits record high in vet medicine nods for second year running

EMA recommended 30 veterinary medicines for marketing authorisation in 2025

Bayer and Vanderbilt launch five-year partnership to accelerate innovative therapies

The partnership initially will focus on cardiovascular and kidney diseases

CORONA Remedies secures EAEU-GMP certification

This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model

Shionogi boosts stake in ViiV Healthcare in $2.125 billion deal, Pfizer exits

Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding

Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator

This marks the second indication for which gumokimab has gained NDA review acceptance

Zydus launches world’s first biosimilar of Nivolumab in India, cutting costs by 75%

iRegene’s Parkinson’s therapy gains FDA designation

The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases

Novo Nordisk deepens Aspect Biosystems alliance in push for curative diabetes cell therapies

Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies

AstraZeneca to withdraw Nasdaq listings ahead of NYSE direct listing

The move follows AstraZeneca’s previously announced plan to complete a direct listing of its Ordinary Shares and debt securities on the New York Stock Exchange